Insider Selling: Scholar Rock (NASDAQ:SRRK) Director Sells $164,068.22 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Kristina Burow sold 3,053 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $53.74, for a total transaction of $164,068.22. Following the sale, the director directly owned 114,657 shares in the company, valued at $6,161,667.18. This trade represents a 2.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Stock Up 0.9%

Shares of Scholar Rock stock traded up $0.48 during trading hours on Monday, reaching $55.36. 1,182,357 shares of the company’s stock were exchanged, compared to its average volume of 1,407,918. The stock has a market cap of $6.63 billion, a P/E ratio of -15.42 and a beta of 0.67. The company has a 50 day moving average of $48.43 and a two-hundred day moving average of $46.59. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71. Scholar Rock Holding Corporation has a fifty-two week low of $27.07 and a fifty-two week high of $56.54.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same quarter last year, the business earned ($0.67) earnings per share. On average, sell-side analysts forecast that Scholar Rock Holding Corporation will post -3.23 EPS for the current fiscal year.

Analyst Ratings Changes

SRRK has been the topic of a number of analyst reports. JPMorgan Chase & Co. upped their price objective on Scholar Rock from $47.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, March 16th. HC Wainwright raised their target price on shares of Scholar Rock from $58.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Wedbush boosted their target price on shares of Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a report on Wednesday, April 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research report on Tuesday, April 21st. Finally, Barclays increased their price target on shares of Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Four analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $56.00.

Institutional Investors Weigh In On Scholar Rock

A number of large investors have recently added to or reduced their stakes in SRRK. Three Seasons Wealth LLC boosted its position in Scholar Rock by 2.1% during the fourth quarter. Three Seasons Wealth LLC now owns 10,968 shares of the company’s stock worth $483,000 after purchasing an additional 222 shares during the period. Values First Advisors Inc. boosted its holdings in shares of Scholar Rock by 1.5% during the 1st quarter. Values First Advisors Inc. now owns 18,850 shares of the company’s stock worth $927,000 after buying an additional 286 shares during the period. IFP Advisors Inc boosted its holdings in shares of Scholar Rock by 294.1% during the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after buying an additional 450 shares during the period. EverSource Wealth Advisors LLC grew its stake in Scholar Rock by 151.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after buying an additional 525 shares during the last quarter. Finally, California State Teachers Retirement System grew its stake in Scholar Rock by 0.9% in the 2nd quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock valued at $2,209,000 after buying an additional 577 shares during the last quarter. Institutional investors own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).